WuXi XDC tender offer reaches 46.5% acceptances, short of control threshold

An update from WuXi XDC Cayman, Inc. ( (HK:2268) ) is now available.

WuXi XDC Cayman Inc. and BioDlink International Company Limited disclosed that a voluntary conditional cash offer for WuXi XDC’s shares and share options has drawn substantial, but not yet controlling, support from stakeholders. As of the first closing date on 13 March 2026, the offeror had secured valid acceptances for about 46.54% of WuXi XDC’s issued share capital and 85.33% of outstanding share options, short of the 60% voting-rights threshold required for the share offer to become unconditional.

The offer structure requires that valid share acceptances reach at least 60% of the company’s voting rights by the closing date for the transaction to proceed, with the options offer dependent on the share offer becoming unconditional. The announcement also clarified that the offeror and its concert parties held no shares or options prior to the offer period and made no additional acquisitions or relevant securities lending during the offer period, underscoring that control would be obtained purely through the public offer if the acceptance condition is ultimately met.

The most recent analyst rating on (HK:2268) stock is a Hold with a HK$65.00 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.

More about WuXi XDC Cayman, Inc.

WuXi XDC Cayman Inc. operates in the biopharmaceutical services sector, with a focus on bioconjugate development and related contract services for global drugmakers. The company is listed in Hong Kong and attracts strategic interest from financial and industry investors seeking control of its platform and growth potential.

Average Trading Volume: 4,400,078

Technical Sentiment Signal: Hold

Current Market Cap: HK$69.76B

See more insights into 2268 stock on TipRanks’ Stock Analysis page.